Feb 19, 2026 11:00am EST New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
Feb 17, 2026 8:00am EST Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
Feb 09, 2026 8:00am EST bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
Jan 07, 2026 8:00am EST bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
Dec 03, 2025 8:00am EST bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
Nov 05, 2025 8:00am EST bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
Oct 28, 2025 8:00am EDT bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
Oct 20, 2025 8:00am EDT bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
Oct 16, 2025 8:00am EDT bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
